Intuitive Surgical: The Curious Case of Executives Cashing Out While the Factory Pipeline Grows

There is a peculiar tension at the heart of Intuitive Surgical right now. The company is pouring money into a new Southeast Asian manufacturing hub, its procedure volumes are climbing at a double-digit clip, and Wall Street analysts are waving buy ratings. Meanwhile, the people who know the business best have spent the past six months doing one thing with their own stock: selling it.

Over the last half-year, 38 open-market insider transactions have been filed — and not a single one was a purchase. The regularity is what stands out. Mark Brosius, the chief manufacturing and supply chain officer, offloaded 77 shares on each of three consecutive days in mid-August at prices between $390.67 and $394.26, then followed up with another 154 shares later that week at $396.37 and $375.57. Director Amy L. Ladd trimmed her position on August 10 and 11, selling 400 and 72 shares at $379.00 and $393.10 respectively. Gary S. Guthart, also a director, disposed of 10,000 shares through a trust on August 11 at exactly $400.00.

None of this is panic selling. Every transaction ran through a Rule 10b5-1 plan — pre-scheduled, automated programs that strip away any suggestion of a knee-jerk reaction to bad news. But the one-way direction of travel is hard to ignore. Executives who consistently sell and never buy are, implicitly, voting for diversification over conviction. That is a perfectly rational choice. It is not, however, a vote of confidence.

The sell-side sees things rather differently. Piper Sandler reaffirmed its buy rating on August 21, and Oppenheimer upgraded the stock from "Perform" to "Outperform" four days earlier. Bank of America and Citi both reiterated their purchase recommendations mid-month, with one price target of $685 floating around the Street. Those calls land at a moment when the company is expanding its operational footprint in a meaningful way.

On August 17, Intuitive signed a lease with the Penang Development Corporation for a new facility in the Bandar Cassia Technology Park in Malaysia. The 316,000-square-foot plant is slated to begin operations in 2028 and should generate more than 1,200 highly skilled jobs by 2032, producing surgical instruments and electromechanical components for the da Vinci system. The investment runs to more than two billion ringgit over five years — a clear statement of intent about the Asia-Pacific market.

The timing is the interesting part. Why build capacity now, when the shares are languishing? The answer lies in the operating numbers rather than the ticker. Second-quarter revenue grew 19 percent to $2.89 billion, with combined da Vinci and Ion procedure volumes up roughly 16 percent. The Ion lung-diagnostic platform was the standout, jumping about 36 percent. That is no longer a side project; it is a second pillar with its own manufacturing requirements.

There is also the competitive calculus. For two decades, Intuitive effectively had the operating room to itself. That era is over. Medtronic's Hugo, Johnson & Johnson's Ottava, Stryker's Mako, plus challengers like CMR's Versius and China's Moon Maestro are all vying for the same tables. Defending market share in that environment demands not just superior technology but cheaper, scalable production. A factory in Southeast Asia is a strategic answer, not a footnote.

The market, however, has yet to buy the narrative. The stock closed Friday at €324.65, up 1.3 percent on the day — a modest sign of stabilization, but the broader picture remains grim. The shares sit roughly 34 percent below their level at the start of the year and about 37 percent beneath the 52-week high of $516.50, reached on January 7. They have recovered about 12 percent from the 52-week low of $289.05, set on July 23, yet remain 4.1 percent under the 50-day moving average and 20 percent below the 200-day line. Technically, the stock is still wounded.

Some of that weakness has little to do with the company's execution. Management has flagged an estimated one-percentage-point drag on gross margin this year from tariffs, with the risk of more if duties escalate further. A first-quarter cyberattack — which did not affect products or ongoing operations but compromised customer and employee data — served as an unwelcome reminder that even medtech giants are exposed to the darker side of digitalization.

When you're managing operational risk — whether it's a supply chain expansion or a cyber threat — the paperwork behind your decisions matters just as much as the strategy. A free toolkit with 41 ready-made templates and checklists helps you document workplace risks properly and stay compliant. Download the free Risk Assessment Toolkit

So the picture is genuinely mixed. Analysts and management are betting on long-term growth through new Asian manufacturing capacity, while insiders quietly diversify their personal wealth. Both positions can be true simultaneously — growth investment and portfolio de-risking are not mutually exclusive. But the divergence between operational strength and share-price performance, and between institutional optimism and insider caution, is worth holding in mind the next time a fresh price target crosses the wire.